Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRAS | P01111 | 2/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 6/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.33 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24231672 | 1.00 | NRAS (0.42) | NRASFLT3ALKUSP30EHMT2 | |
| SCHEMBL26359492 | 0.90 | NRAS (0.36) | NRASFLT3USP30RIPK1PIK3CD | |
| SCHEMBL24231731 | 0.87 | NRAS (0.47) | NRASFLT3ALKUSP30EHMT2 | |
| SCHEMBL24231384 | 0.82 | FLT3 (0.51) | NRASFLT3IGF1R | |
| SCHEMBL25990669 | 0.82 | FLT3 (0.51) | NRASFLT3IGF1R | |
| SCHEMBL30698359 | 0.81 | ALK (0.35) | NRASFLT3ALKUSP30EHMT2 | |
| SCHEMBL24231361 | 0.80 | FLT3 (0.57) | NRASFLT3CDK2 | |
| SCHEMBL25992527 | 0.80 | FLT3 (0.57) | NRASFLT3CDK2 | |
| SCHEMBL25988954 | 0.80 | FLT3 (0.57) | NRASFLT3CDK2 | |
| SCHEMBL30248534 | 0.77 | USP30 (0.36) | NRASFLT3ALKUSP30EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER | 2023-09-28 | — | — | US | disclosed |
| WO-2022026935-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303563-A1 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | FLT3, IRAK2, IRAK3 | NRAS 259/4885FLT3 1/4885ALK 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.